Search Page

1

Cite

Share

Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.

Vokes EE, Chu E. Vokes EE, et al. Among authors: chu e. Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25. Oncology (Williston Park). 2006. PMID: 16736979 Review.

Cite

Share

2

Cite

Share

The IGF-1R pathway as a therapeutic target.

Chu E. Chu E. Oncology (Williston Park). 2011 May;25(6):538-9, 543. Oncology (Williston Park). 2011. PMID: 21717909 No abstract available.

Cite

Share

3

Cite

Share

Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer.

Lee JJ, Chu E. Lee JJ, et al. Among authors: chu e. Clin Colorectal Cancer. 2018 Dec;17(4):258-273. doi: 10.1016/j.clcc.2018.06.004. Epub 2018 Jun 21. Clin Colorectal Cancer. 2018. PMID: 30072278 Free PMC article. Review.

Cite

Share

4

Cite

Share

The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells.

Wei N, Chu E, Wu SY, Wipf P, Schmitz JC. Wei N, et al. Among authors: chu e. Oncotarget. 2015 Mar 10;6(7):4745-56. doi: 10.18632/oncotarget.2938. Oncotarget. 2015. PMID: 25544765 Free PMC article.

Cite

Share

5

Cite

Share

Protein kinase d as a potential chemotherapeutic target for colorectal cancer.

Wei N, Chu E, Wipf P, Schmitz JC. Wei N, et al. Among authors: chu e. Mol Cancer Ther. 2014 May;13(5):1130-41. doi: 10.1158/1535-7163.MCT-13-0880. Epub 2014 Mar 14. Mol Cancer Ther. 2014. PMID: 24634417 Free PMC article.

Cite

Share

6

Cite

Share

Phase I study of veliparib in combination with gemcitabine.

Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH. Stoller R, et al. Among authors: chu e. Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. Epub 2017 Aug 2. Cancer Chemother Pharmacol. 2017. PMID: 28770300 Free PMC article. Clinical Trial.

Cite

Share

7

Cite

Share

Personalized medicine in the adjuvant chemotherapy of stage II colon cancer--are we there yet?

Lee JJ, Chu E. Lee JJ, et al. Among authors: chu e. Oncology (Williston Park). 2013 Aug;27(8):754, 756-8. Oncology (Williston Park). 2013. PMID: 24133821 No abstract available.

Cite

Share

8

Cite

Share

The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More?

Lee JJ, Chu E. Lee JJ, et al. Among authors: chu e. Oncology (Williston Park). 2018 Sep 15;32(9):437-42, 444. Oncology (Williston Park). 2018. PMID: 30248163 Review.

Cite

Share

9

Cite

Share

How I treat chemorefractory metastatic colorectal cancer.

Chu E. Chu E. Clin Adv Hematol Oncol. 2018 May;16(5):340-345. Clin Adv Hematol Oncol. 2018. PMID: 29851930 No abstract available.

Cite

Share

10

Cite

Share

Can metastatic colorectal cancer be cured?

Bartlett DL, Chu E. Bartlett DL, et al. Among authors: chu e. Oncology (Williston Park). 2012 Mar;26(3):266-75. Oncology (Williston Park). 2012. PMID: 22545311 Review.

Cite

Share